



ALK Positive Lung Cancer (UK)

A patient-focused charity that

SUPPORTS

EMPOWERS

ADVOCATES


Side Effects arising from the use of Alectinib, Brigatinib and Lorlatinib: real-world data collected and analysed by the Charity

The data presented is based on the results of several surveys the Charity has carried out of its members


The surveys were conducted online and completed by between 93 and 99 ALK-positive lung cancer patients



**Alectinib Side Effects Reported
by at Least 20% of Respondents (n=79)**




**Brigatinib Side Effects Reported
by at Least 20% of Respondents (n=14)**




Support Empower Advocate

**Lorlatinib Side Effects Reported
by at Least 20% of Respondents (n=14)**




Support Empower Advocate

Considering Only Side Effects, Did the Patient Prefer to Take Alectinib or Lorlatinib?




Frequency of Selected Side Effects (Alectinib n=79: Brigatinib n=14: Lorlatinib n=14)




Support Empower Advocate

Incidence of severe fatigue whilst taking a TKI




Treatment Paused due to severe side effects/toxicity


Alectinib n=79



Brigatinib n=18




Lorlatinib n=13
8%




Dose Reduction due to severe side effects/toxicity


Alectinib n=78



Brigatinib n=18



Lorlatinib n=11



Caveat

Alectinib, in particular, and Brigatinib have been in use for much longer than Lorlatinib.


As patients spend longer on Lorlatinib, it can be expected the frequency of pausing in treatment and dose reduction will increase.



Support Empower Advocate


Alectinib & Brigatinib (n=95)

Frequency Treatment Paused



No. of times treatment paused


Frequency of Dose Reduction



No. of times dose reduced


Alectinib & Brigatinib (n=95)

Causes of Pause in Treatment



■ toxicity ■ other side effects ■ other reasons

Causes of Dose Reduction




■ toxicity ■ other side effects ■ other reasons

“Other Reasons” for pausing treatment


- Sickness
- Dental treatment
- Covid-19 (3)
- Taking antibiotics
- Pneumonitis (2)
- Drug interaction
- Prior to medical procedure

Alectinib & Brigatinib

What followed first pause in Treatment
(n=38)



What followed first dose reduction
(n=29)



Summary of Results

Alectinib had the highest frequency of side effects

Brigatinib had the lowest frequency of side effects

30%-45% of patients taking Lorlatinib experienced visual, cognitive, mood or hallucinatory effects

39% of patients had their treatment paused at least once. About half returned to a full dose and half went onto a reduced dose

29% of patients had their dose reduced

Acknowledgement

To our members who provided the real-world data that has been presented here.



Support Empower Advocate